Literature DB >> 27678280

Introduction of revised "Aims and Scope" for Clinical & Experimental Metastasis.

Jonathan P Sleeman1,2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27678280     DOI： 10.1007/s10585-016-9823-9

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN： 0262-0898            Impact factor:   5.150


× No keyword cloud information.
  10 in total

Review 1.  The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms.

Authors:  Yue Teng; Xu Li
Journal:  Clin Exp Metastasis       Date:  2013-10-26       Impact factor: 5.150

2.  Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells.

Authors:  Manohar C Dange; Nithya Srinivasan; Shyam K More; Sanjay M Bane; Archana Upadhya; Arvind D Ingle; Rajiv P Gude; Rabindranath Mukhopadhyaya; Rajiv D Kalraiya
Journal:  Clin Exp Metastasis       Date:  2014-06-21       Impact factor: 5.150

3.  Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases.

Authors:  Leandro Marcelo Martinez; Valeria Beatriz Fernández Vallone; Vivian Labovsky; Hosoon Choi; Erica Leonor Hofer; Leonardo Feldman; Raúl Horacio Bordenave; Emilio Batagelj; Federico Dimase; Ana Rodriguez Villafañe; Norma Alejandra Chasseing
Journal:  Clin Exp Metastasis       Date:  2013-10-31       Impact factor: 5.150

4.  Decreased expression of RASSF1A and up-regulation of RASSF1C is associated with esophageal squamous cell carcinoma.

Authors:  Wei Guo; Lei Cui; Cong Wang; Yanli Guo; Supeng Shen; Gang Kuang; Zhiming Dong
Journal:  Clin Exp Metastasis       Date:  2014-04-23       Impact factor: 5.150

5.  Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.

Authors:  Dana M Roque; Natalia Buza; Michelle Glasgow; Stefania Bellone; Ileana Bortolomai; Sara Gasparrini; Emiliano Cocco; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2013-09-05       Impact factor: 5.150

Review 6.  The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toshiro Terachi; Toyoaki Uchida; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2014-01       Impact factor: 5.150

7.  Capsaicin suppresses the migration of cholangiocarcinoma cells by down-regulating matrix metalloproteinase-9 expression via the AMPK-NF-κB signaling pathway.

Authors:  Gong-Rak Lee; Soo Hwa Jang; Chang Jae Kim; Ah-Ram Kim; Dong-Joon Yoon; Neung-Hwa Park; In-Seob Han
Journal:  Clin Exp Metastasis       Date:  2014-09-14       Impact factor: 5.150

8.  Breast cancer nodal metastasis correlates with tumour and lymph node methylation profiles of Caveolin-1 and CXCR4.

Authors:  Leonidas Alevizos; Agapi Kataki; Anastasia Derventzi; Ilias Gomatos; Christos Loutraris; Georgia Gloustianou; Andreas Manouras; Manousos M Konstadoulakis; George Zografos
Journal:  Clin Exp Metastasis       Date:  2014-03-04       Impact factor: 5.150

9.  RANK expression on breast cancer cells promotes skeletal metastasis.

Authors:  Michelle L Blake; Mark Tometsko; Robert Miller; Jon C Jones; William C Dougall
Journal:  Clin Exp Metastasis       Date:  2013-11-24       Impact factor: 5.150

10.  CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice.

Authors:  Patrick Brennecke; Matthias J E Arlt; Carmen Campanile; Knut Husmann; Ana Gvozdenovic; Tiziana Apuzzo; Marcus Thelen; Walter Born; Bruno Fuchs
Journal:  Clin Exp Metastasis       Date:  2014-01-04       Impact factor: 5.150
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.